Identification
- Summary
Chlorphenoxamine is an antihistamine used as an antipruritic.
- Generic Name
- Chlorphenoxamine
- DrugBank Accession Number
- DB09007
- Background
Chlorphenoxamine is marketed under the name Phenoxene. It is an antihistamine and anticholinergic used to treat itching as well as for its antiparkinsonian effect.
- Type
- Small Molecule
- Groups
- Withdrawn
- Structure
Structure for Chlorphenoxamine (DB09007)
- Weight
- Average: 303.826
Monoisotopic: 303.138992038 - Chemical Formula
- C18H22ClNO
- Synonyms
- Chlorphenoxamine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
Pathway Category Chlorphenoxamine H1-Antihistamine Action Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAclidinium The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Aclidinium. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Chlorphenoxamine. Alfentanil The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Alfentanil. Alloin The therapeutic efficacy of Alloin can be decreased when used in combination with Chlorphenoxamine. Amantadine The risk or severity of adverse effects can be increased when Amantadine is combined with Chlorphenoxamine. Ambenonium The therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Ambenonium. Amitriptyline The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Amitriptyline. Amitriptylinoxide The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Amitriptylinoxide. Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Chlorphenoxamine. Amoxapine The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Amoxapine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Chlorphenoxamine hydrochloride 5I159322PY 562-09-4 PAQUKACYLLABHB-UHFFFAOYSA-N - International/Other Brands
- Sistral (I.E. Ulagay) / Systral (Altian)
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image ซีสทราล ครีม Cream 150 %w/w Topical บริษัท อินเตอร์ไทย ฟาร์มาซูติเคิ้ล แมนูแฟคเจอริ่ง จำกัด จำกัด 2003-05-09 Not applicable Thailand 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image SISTRAL C DRAJE , 20 ADET Chlorphenoxamine hydrochloride (20 mg) + Caffeine (50 mg) Tablet, coated Topical İ.E. ULAGAY İLAÇ SAN. TÜRK A.Ş. 2020-08-14 2021-09-15 Turkey 
Categories
- ATC Codes
- D04AA34 — Chlorphenoxamine
- D04AA — Antihistamines for topical use
- D04A — ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
- D04 — ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
- D — DERMATOLOGICALS
- R06AA — Aminoalkyl ethers
- R06A — ANTIHISTAMINES FOR SYSTEMIC USE
- R06 — ANTIHISTAMINES FOR SYSTEMIC USE
- R — RESPIRATORY SYSTEM
- Drug Categories
- Agents producing tachycardia
- Amines
- Aminoalkyl Ethers
- Anticholinergic Agents
- Antihistamines for Systemic Use
- Antihistamines for Topical Use
- Antipruritics, Incl. Antihistamines, Anesthetics, Etc.
- Cholinergic Agents
- Dermatologicals
- Histamine Agents
- Histamine Antagonists
- Muscarinic Antagonists
- Neurotransmitter Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylmethanes
- Direct Parent
- Diphenylmethanes
- Alternative Parents
- Benzylethers / Chlorobenzenes / Aryl chlorides / Trialkylamines / Dialkyl ethers / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
- Substituents
- Amine / Aromatic homomonocyclic compound / Aryl chloride / Aryl halide / Benzylether / Chlorobenzene / Dialkyl ether / Diphenylmethane / Ether / Halobenzene
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 3UVD77BP8R
- CAS number
- 77-38-3
- InChI Key
- KKHPNPMTPORSQE-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H22ClNO/c1-18(21-14-13-20(2)3,15-7-5-4-6-8-15)16-9-11-17(19)12-10-16/h4-12H,13-14H2,1-3H3
- IUPAC Name
- {2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl}dimethylamine
- SMILES
- CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
References
- Synthesis Reference
U.S. Patent 2,785,202.
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0240223
- KEGG Drug
- D07198
- PubChem Compound
- 6475
- PubChem Substance
- 310264966
- ChemSpider
- 6230
- 20881
- ChEBI
- 135288
- ChEMBL
- CHEMBL2110774
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Chlorphenoxamine
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intramuscular; Intravenous 1 ml Tablet, coated Topical Cream Topical 40 gr Cream Topical 20 gr Gel Topical 20 g Cream Topical 150 %w/w - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 128 U.S. Patent 2,785,202. - Predicted Properties
Property Value Source Water Solubility 0.00582 mg/mL ALOGPS logP 4.45 ALOGPS logP 4.4 Chemaxon logS -4.7 ALOGPS pKa (Strongest Basic) 8.87 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 12.47 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 89.57 m3·mol-1 Chemaxon Polarizability 34.03 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at June 20, 2014 00:14 / Updated at May 29, 2021 18:11